ARROWHEAD PHARMACEUTICALS INC

For the period ended Sep 30, 2024. Filed Nov 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Nov 26, 2024

ARWR$49.24-15.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 26, 2024

ARROWHEAD PHARMACEUTICALS, INC.
By:	/s/ Christopher Anzalone
	Christopher Anzalone
	Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Christopher Anzalone
Signature	Title	Date
/s/ Christopher Anzalone	Chief Executive Officer, President and Director (Principal Executive Officer)	November 26, 2024
/s/ Kenneth A. Myszkowski	Chief Financial Officer (Principal Financial and Accounting Officer)	November 26, 2024
Kenneth A. Myszkowski
/s/ Douglass Given	Director, Chairman of the Board of Directors	November 26, 2024
Douglass Given
/s/ Mauro Ferrari	Director	November 26, 2024
Mauro Ferrari
/s/ Michael S. Perry	Director	November 26, 2024
Michael S. Perry
/s/ William Waddill	Director	November 26, 2024
William Waddill
/s/ Adeoye Olukotun	Director	November 26, 2024
Adeoye Olukotun
/s/ Victoria Vakiener	Director	November 26, 2024
Victoria Vakiener
/s/ Hongbo Lu	Director	November 26, 2024
Hongbo Lu

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.